A prospective study of tardive dyskinesia in Japan

  title={A prospective study of tardive dyskinesia in Japan},
  author={Toshiya Inada and Kimio Ohnishi and M. Kamisada and Genichi Matsuda and Osamu Tajima and Yoshiaki Yanagisawa and Kimiaki Hashiguchi and Satoru Shima and Yoshinori Oh-e and Yoshinobu Masuda and Tomoyuki Chiba and Kunitoshi Kamijima and R W Rockhold and Gohei Yagi},
  journal={European Archives of Psychiatry and Clinical Neuroscience},
  • T. Inada, K. Ohnishi, G. Yagi
  • Published 2005
  • Medicine, Psychology
  • European Archives of Psychiatry and Clinical Neuroscience
SummaryA large-scale, prospective study of tardive dyskinesia (TD) was performed in 11 psychiatric facilities in Japan. A total of 1595 psychiatric patients were enrolled in this study in 1987. The progress of these patients, with the exception of 490 dropouts, has now been followed up to 1988. The prevalence of TD at study entry was 7.6%, the annual incidence rate was 3.7% and the annual remission rate was 28.7%. Newly developed TD patients tended to be older, to have undergone more… 
Tardive and spontaneous dyskinesia incidence in the general population
Diabetes, psychoses, and especially schizophrenia are positively associated with SD and TD, with persons with schizophrenia having 4.4 times greater risk of SD than those without the disease.
Non‐therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: A meta‐analysis
Despite many reported risk factors for TD in schizophrenia, little conclusive evidence exists to corroborate this, however, the fact that early EPS predicts onset of TD has important clinical and research implications.
Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and test–retest reliability
The Norwegian version of the DIEPSS is a reliable instrument for the assessment of drug-induced EPSs, and inter-rater and test–retest agreement exhibited satisfactory ICC levels above 0.70.
5 Dystonia Secondary to Use of Antipsychotic Agents
Second-generation antipsychotics were developed and introduced, including risperidone in 1996, quetiapine, perospirone, and olanzapine in 2001, aripiprazole in 2006, and blonanserin in 2008, primarily on the basis of their reduced risk of inducing EPS.
Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited
The aim of this study was to review mechanism(s) of action and pharmacokinetic‐pharmacodynamic properties of metoclopramide, as well as the risk of meetingoclopamide‐induced tardive dyskinesia, factors that may change drug exposure in humans, and to summarize the clinical context for appropriate use of the drug.
Dystonia Secondary to Use of Antipsychotic Agents
Second-generation antipsychotics were developed and introduced, including risperidone in 1996, quetiapine, perospirone, and olanzapine in 2001, aripiprazole in 2006, and blonanserin in 2008, primarily on the basis of their reduced risk of inducing EPS.
Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients
The present results suggest that the homozygotes of CYP2D6*2 and CYP6*10 appear to be a susceptibility factor for developing acute EPS in schizophreniaic patients and for impaired neuroleptic metabolism in Japanese schizophrenic patients.
A systematic review of atypical antipsychotic drugs in schizophrenia.
The main objectives were to assess the clinical effectiveness, safety and cost-effectiveness of 'atypical' antipsychotic drugs in schizophrenia in comparison with conventional anti-schizophrenia drugs, placebo and other atypical antipsychotics.


Tardive dyskinesia: prevalence and risk factors, 1959 to 1979
Prevalence surveys of tardive dyskinesia in neuroleptic-treated patients are reviewed and it is suggested that advancing age and female sex are the two variables most consistently associated with increased prevalence.
Prevalence of tardive dyskinesia.
: Forty-four epidemiologic studies on tardive dyskinesia were evaluated as to whether they provided information on diagnostic criteria, objective scale and assessment, interobserver reliability,
Tardive dyskinesia: a 3-year follow-up study.
The amount of purposeless trunk and limb movement present proved to be a relatively stable phenomenon, showing only a slight increase with age and no change over the follow-up period.
A Prospective Study of Tardive Dyskinesia Development: Preliminary Results
Preliminary findings from a prospective study of tardive dyskinesia (TD) development in a population of psychiatric patients suggest a TD incidence of 12% after 4 years of cumulative neuroleptic
Tardive dyskinesia.
An ongoing prospective study suggests that the annual incidence of tardive dyskinesia in patients over age 45 is over 30 percent, and likely risk factors include female gender, mood disorders, "organic" brain dysfunction or damage, diabetes mellitus, and early extrapyramidal side effects.
Drug-induced tardive dyskinesia.
  • H. Itoh
  • Psychology, Medicine
    Current developments in psychopharmacology
  • 1981
It is estimated that 10 to 30 percent of long-term hospitalized psychiatric patients in Europe and North America exhibit tardive dyskinesia, whereas 5 to 20 percent of patients in Japan, and the author stresses that the early diagnosis of dyskinetic symptoms, possible removal of responsible drugs, and preventive care in daily psychotropic drug treatment are regarded as extremely important in the management of this syndrome.
A 10-year follow-up study of tardive dyskinesia--with special reference to the influence of neuroleptic administration on the long-term prognosis.
It is speculated that the long-term outcome of TD is determined mainly by the age at onset, however, if the continued administration of NLP is combined with aging, reversible TD observed among young patients may recur or become persistent.
Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study.
The TD group had a significantly higher MR during 10 years as compared with the control group, but critical factors could not be revealed to explain why the TD patients had the higher MR.
Persistent dyskinesia after long-term treatment with neuroleptics in Japan: its present status and clinical problems.
It was stressed that the earlier diagnosis and earlier re-moval of the drug were important for the prophylaxis of irreversible persistent dysKinesia and that close relationship of persistent dyskinesia with the other types of extrapyramidal reaction should be taken into consideration for the prediction of the symptom.
Follow-up study of 11 patients with potentially reversible tardive dyskinesia.
  • G. Yagi, H. Itoh
  • Psychology, Medicine
    The American journal of psychiatry
  • 1987
The authors followed the course of 11 patients with potentially reversible tardive dyskinesia while they were taking minimum effective neuroleptic doses. After 10 years, the symptoms of tardive